These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date, and reported results 2007-001997-97 COMPARISON OF 2 CHEMOTHERAPY REGIMENS IN NON SMALL CELL LUNG CANCER PATIENTS RELAPSING AFTER SURGERY AND PERI OPERATIVE CHEMOTHERAPY A RANDOMIZED PHASE III STUDY. bad-data
Completed, but no date Terminated 2008-004897-41 A randomized, double-blind, placebo-controlled Phase II-III multi-centre study to evaluate the effect of adjuvant pazopanib (GW786034) versus placebo on post-surgical disease-free survival in patients... bad-data
Completed, but no date Terminated 2008-004939-38 Essai randomisé de phase II/III évaluant une stratégie thérapeutique post-opératoire individualisée chez les patients opérés d’un carcinome bronchique non à petites cellules (CBNPC) non épidermoïde de... bad-data
Completed, but no date, and reported results 2009-010187-42 Etude de phase II-III randomisée comparant bevacizumab 7,5 mg/kg en association avec la chimiothérapie versus la chimiothérapie seule dans les cancers bronchiques à petites cellules étendus et chimios... bad-data
Completed, but no date Terminated 2009-012412-41 Etude de phase II évaluant l’association de cetuximab à une radiothérapie et chimiothérapie concomitante par cisplatine et pemetrexed dans le traitement des cancers bronchiques non à petites cellules ... bad-data
Not reported 2012-004524-38 Phase III study comparing the efficacy of paclitaxel-bevacizumab with docetaxel in 2nd or 3rd line of treatment of non squamous Non Small Cells Lung Cancer 2017-04-12 due-trials
Ongoing 2012-005520-15 Phase III study comparing maintenance by pemetrexed or gemcitabine to surveillance in elderly patient (≥ 70 year old) with advanced Non Small Cell Lung Cancer controlled by induction chemotherapy not-yet-due
Ongoing 2015-003390-15 Phase II study evaluating the combination of cetuximab with afatinib as first-line treatment for patients with EGFR mutated Non Small Cell Lung Cancer not-yet-due
Ongoing 2015-004475-75 A randomized phase II study evaluating efficacy and safety of 2nd or 3rd line treatment by Nivolumab monotherapy or Nivolumab plus Ipilimumab, for unresectable Malignant Pleural Mesothelioma (MPM) pat... not-yet-due
Ongoing 2016-001849-15 A PHASE II PROSPECTIVE IMMUNE NEOADJUVANT THERAPY STUDY OF DURVALUMAB (MEDI4736) IN EARLY STAGE NON-SMALL CELL LUNG CANCER not-yet-due
Ongoing 2016-003795-49 A randomized multicenter, open label, controlled and non-comparative phase II study of anti–PDL1 ATEZOLIZUMAB (MPDL3280A) or chemotherapy as second-line therapy in patients with small cell lung cancer... not-yet-due
Ongoing 2016-003796-22 Immunotherapy by Nivolumab after prior Chemotherapy for HIV+ patients with Advanced non-small cell lung cancer (NSCLC): IFCT-CHIVA2 phase IIa trial not-yet-due
Ongoing 2017-002540-33 A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with PDL1-positive stage IV Non-Small Cell... not-yet-due
Ongoing 2017-002561-21 Randomised Open Label Adaptive Phase III trial of addition of Belinostat to chemotherapy in patients with locally advanced potentially resectable Thymic Epithelial Tumors (TET) not-yet-due